Q1 Earnings Estimate for OmniAb Issued By Leerink Partnrs

OmniAb, Inc. (NASDAQ:OABI - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2026 earnings estimates for OmniAb in a research note issued on Thursday, April 17th. Leerink Partnrs analyst P. Souda forecasts that the company will post earnings per share of ($0.16) for the quarter. The consensus estimate for OmniAb's current full-year earnings is ($0.61) per share. Leerink Partnrs also issued estimates for OmniAb's Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.15) EPS and Q4 2026 earnings at ($0.15) EPS.

OABI has been the subject of a number of other research reports. Benchmark dropped their price objective on OmniAb from $8.00 to $6.00 and set a "buy" rating for the company in a research note on Thursday, March 20th. Royal Bank of Canada lowered their price objective on shares of OmniAb from $7.00 to $4.00 and set an "outperform" rating for the company in a research note on Thursday, March 27th. Finally, HC Wainwright reissued a "buy" rating and issued a $11.00 target price on shares of OmniAb in a research note on Wednesday, March 19th.

OmniAb Stock Up 4.1 %

Shares of NASDAQ OABI traded up $0.08 during midday trading on Friday, reaching $1.91. The company had a trading volume of 542,419 shares, compared to its average volume of 573,871. The stock has a market cap of $232.67 million, a PE ratio of -3.07 and a beta of 0.06. OmniAb has a one year low of $1.70 and a one year high of $4.96. The firm's fifty day moving average price is $2.74 and its 200-day moving average price is $3.41.

OmniAb (NASDAQ:OABI - Get Free Report) last issued its earnings results on Tuesday, March 18th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. OmniAb had a negative net margin of 308.78% and a negative return on equity of 20.97%. The company had revenue of $10.80 million for the quarter, compared to analysts' expectations of $10.13 million. During the same quarter last year, the company earned ($0.14) EPS.

Insider Activity at OmniAb

In other news, CEO Matthew W. Foehr sold 13,964 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $3.68, for a total transaction of $51,387.52. Following the sale, the chief executive officer now owns 3,798,682 shares in the company, valued at approximately $13,979,149.76. The trade was a 0.37 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Kurt A. Gustafson sold 7,255 shares of the stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $3.67, for a total transaction of $26,625.85. Following the completion of the transaction, the chief financial officer now owns 206,211 shares of the company's stock, valued at approximately $756,794.37. The trade was a 3.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 67,985 shares of company stock worth $189,773 over the last ninety days. 8.60% of the stock is owned by corporate insiders.

Institutional Trading of OmniAb

Hedge funds have recently made changes to their positions in the stock. Invesco Ltd. boosted its stake in OmniAb by 3.3% during the 4th quarter. Invesco Ltd. now owns 93,653 shares of the company's stock valued at $332,000 after purchasing an additional 2,997 shares during the last quarter. Connors Investor Services Inc. boosted its position in shares of OmniAb by 18.4% during the fourth quarter. Connors Investor Services Inc. now owns 29,611 shares of the company's stock valued at $105,000 after buying an additional 4,611 shares during the last quarter. SG Americas Securities LLC increased its holdings in OmniAb by 16.5% in the 4th quarter. SG Americas Securities LLC now owns 40,609 shares of the company's stock worth $144,000 after buying an additional 5,751 shares in the last quarter. Sherbrooke Park Advisers LLC raised its position in OmniAb by 53.5% in the 4th quarter. Sherbrooke Park Advisers LLC now owns 17,226 shares of the company's stock worth $61,000 after buying an additional 6,001 shares during the last quarter. Finally, Isthmus Partners LLC boosted its holdings in shares of OmniAb by 1.6% during the 4th quarter. Isthmus Partners LLC now owns 453,135 shares of the company's stock valued at $1,604,000 after acquiring an additional 7,001 shares during the last quarter. 72.08% of the stock is owned by institutional investors.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.